COVID‐19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock

Harari, Rafael; Bangalore, Sripal; Chang, Ernest W.; Shah, Binita

doi:10.1002/ccd.28992

Cited by 40 publications

(38 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, three of these patients had no cardiovascular risk factors or significant comorbidities 24 . Further reports from Germany and the USA have also mentioned cardiogenic shock as a significant complication of COVID‐19 25,26 . Based on all studies, approximately 8% of patients developed heart failure/cardiogenic shock as a manifestation of COVID‐19.…”

Section: Resultsmentioning

confidence: 95%

Cardiac manifestations in COVID‐19 patients—A systematic review

et al. 2020

View full text Add to dashboard Cite

Objectives The coronavirus disease‐2019 (COVID‐19) pandemic has resulted in the worst global pandemic of our generation, affecting 215 countries with nearly 5.5 million cases. The association between COVID‐19 and the cardiovascular system has been well described. We sought to systematically review the current published literature on the different cardiac manifestations and the use of cardiac‐specific biomarkers in terms of their prognostic value in determining clinical outcomes and correlation to disease severity. Methods A systematic literature review across PubMed, Cochrane database, Embase, Google Scholar, and Ovid was performed according to PRISMA guidelines to identify relevant articles that discussed risk factors for cardiovascular manifestations, cardiac manifestations in COVID‐19 patients, and cardiac‐specific biomarkers with their clinical implications on COVID‐19. Results Sixty‐one relevant articles were identified which described risk factors for cardiovascular manifestations, cardiac manifestations (including heart failure, cardiogenic shock, arrhythmia, and myocarditis among others) and cardiac‐specific biomarkers (including CK‐MB, CK, myoglobin, troponin, and NT‐proBNP). Cardiovascular risk factors can play a crucial role in identifying patients vulnerable to developing cardiovascular manifestations of COVID‐19 and thus help to save lives. A wide array of cardiac manifestations is associated with the interaction between COVID‐19 and the cardiovascular system. Cardiac‐specific biomarkers provide a useful prognostic tool in helping identify patients with the severe disease early and allowing for escalation of treatment in a timely fashion. Conclusion COVID‐19 is an evolving pandemic with predominate respiratory manifestations, however, due to the interaction with the cardiovascular system; cardiac manifestations/complications feature heavily in this disease, with cardiac biomarkers providing important prognostic information.

show abstract

Section: Resultsmentioning

confidence: 95%

Cardiac manifestations in COVID‐19 patients—A systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal, neurological, and other atypical manifestations are also reported [ 2 , 3 ]. Cardiovascular manifestations are relatively rare; however, the acute coronary syndrome is reported [ [4] , [5] , [6] , [7] ]. Our patient had no risk factors for coronary artery disease but developed an acute STEMI, and PPCI revealed complete thrombosis of LAD.…”

Section: Discussionmentioning

confidence: 99%

“…There are reports of coronary thrombus in a young patient with risk factors for CAD and stent thrombosis in established CAD [ 5 , 10 ]. However, our patient was different as he was young with no conventional cardiovascular risk factors other than being a male.…”

Section: Discussionmentioning

confidence: 99%

Coronary thrombosis in a young male with COVID-19

Shams

Ata

Mushtaq

et al. 2020

IDCases

View full text Add to dashboard Cite

show abstract

“… 22 Spain Case series 4 4 (100) 50–76 3 (75) Aortoiliac 2; CNS-1; aortic arch 1; thoracic aorta 1; common carotid 1 CT angiography DVT, PE HTN, dyslipidemia 1 (25) Harari et al. 23 USA Case report 1 1 (100) 40 0 (0) Heart (left coronary artery) Coronary angiography None DM, HTN, hyperlipidemia, and schizophrenia 1 (100) Helms et al. 24 France Cohort 150 4 (2.7) - - CNS (cerebellar arteries) (2); lower limb (1); abdomen SMA (1) MRI and CT None Cardiovascular disease, diabetes, chronic renal disease Not reported Kashi et al.…”

Section: Methodsmentioning

confidence: 99%

Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review

Cheruiyot

Kipkorir

Ngure

et al. 2021

Annals of Vascular Surgery

149

153

View full text Add to dashboard Cite

Background Emerging evidence suggests that severe form of coronavirus disease 2019 (COVID-19) is mediated, in part, by a hypercoagulable state characterized by micro- and macro-vascular thrombotic angiopathy. Although venous thrombotic events in COVID-19 patients have been well described, data on arterial thrombosis (AT) in these patients is still limited. We, therefore, conducted a rapid systematic review of current scientific literature to identify and consolidate evidence of AT in COVID-19 patients. Methods A systematic search of literature was conducted between November 1, 2019, and June 9, 2020, on PubMed and China National Knowledge Infrastructure to identify potentially eligible studies. Results A total of 27 studies (5 cohort, 5 case series, and 17 case reports) describing arterial thrombotic events in 90 COVID-19 patients were included. The pooled incidence of AT in severe/critically ill intensive care unit–admitted COVID-19 patients across the 5 cohort studies was 4.4% (95% confidence interval 2.8–6.4). Most of the patients were male, elderly, and had comorbidities. AT was symptomatic in >95% of these patients and involved multiple arteries in approximately 18% of patients. The anatomical distribution of arterial thrombotic events was wide, occurring in limb arteries (39%), cerebral arteries (24%), great vessels (aorta, common iliac, common carotid, and brachiocephalic trunk; 19%), coronary arteries (9%), and superior mesenteric artery (8%). The mortality rate in these patients is approximately 20%. Conclusions AT occurs in approximately 4% of critically ill COVID-19 patients. It often presents symptomatically and can affect multiple arteries. Further investigation of the underlying mechanism of AT in COVID-19 would be needed to clarify possible therapeutic targets.

show abstract

COVID‐19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock

Cited by 40 publications

References 14 publications

Cardiac manifestations in COVID‐19 patients—A systematic review

Cardiac manifestations in COVID‐19 patients—A systematic review

Coronary thrombosis in a young male with COVID-19

Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review

Contact Info

Product

Resources

About